![conference banner](/images/conference-banner.jpeg)
Abstract
The prevalence of diabetes and its complications is increasing worldwide. Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease. Although angiotensin-converting-enzyme inhibitors have been cited as the first line of therapy for the management of microalbuminuria, the rate of remission from microalbuminuria to normoalbuminuria has been lower than the expected. Furthermore, due to the elevated frequency of side effects of the rennin-angiotensin blockers new approaches for the treatment of microalbuminuria are needed. Pentoxifylline, a xanthine derivate drug with hemorheologic properties and primarily indicated for the therapy of disturbances of blood fluidity, is also an antagonist of adenosine 2 receptors and have antiinflammatory and immunomodulatory effects, properties that promote beneficial changes in the blood flow conditions and kidney function. Current evidence shows that the short-term use of pentoxifylline has low side-effects, reduces both proteinuria and microalbuminuria in subjects with diabetes, and is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients. Although this data suggests that pentoxifylline could be useful for preventing the development of end-stage renal disease is necessary to conduct long-term studies to evaluate the role of pentoxifylline in the treatment of diabetic nephropathy and the prevention of chronic renal failure. In this article, we review the clinical evidence that show the efficacy of pentoxifylline in the management of microalbuminuria in diabetic patients.
Keywords: Pentoxifylline, Diabetic nephropathy, Microalbuminuria, Proteinuria
Current Diabetes Reviews
Title: Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Volume: 4 Issue: 1
Author(s): Martha Rodriguez-Moran and Fernando Guerrero-Romero
Affiliation:
Keywords: Pentoxifylline, Diabetic nephropathy, Microalbuminuria, Proteinuria
Abstract: The prevalence of diabetes and its complications is increasing worldwide. Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease. Although angiotensin-converting-enzyme inhibitors have been cited as the first line of therapy for the management of microalbuminuria, the rate of remission from microalbuminuria to normoalbuminuria has been lower than the expected. Furthermore, due to the elevated frequency of side effects of the rennin-angiotensin blockers new approaches for the treatment of microalbuminuria are needed. Pentoxifylline, a xanthine derivate drug with hemorheologic properties and primarily indicated for the therapy of disturbances of blood fluidity, is also an antagonist of adenosine 2 receptors and have antiinflammatory and immunomodulatory effects, properties that promote beneficial changes in the blood flow conditions and kidney function. Current evidence shows that the short-term use of pentoxifylline has low side-effects, reduces both proteinuria and microalbuminuria in subjects with diabetes, and is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients. Although this data suggests that pentoxifylline could be useful for preventing the development of end-stage renal disease is necessary to conduct long-term studies to evaluate the role of pentoxifylline in the treatment of diabetic nephropathy and the prevention of chronic renal failure. In this article, we review the clinical evidence that show the efficacy of pentoxifylline in the management of microalbuminuria in diabetic patients.
Export Options
About this article
Cite this article as:
Rodriguez-Moran Martha and Guerrero-Romero Fernando, Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes, Current Diabetes Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339908783502343
DOI https://dx.doi.org/10.2174/157339908783502343 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with an increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to microcirculatory disturbances and reduced levels of endogenous growth factors. Delayed cutaneous wound healing is a chronic ...read more
Oxidative and Inflammatory Responses in the Development of Secondary Diabetic Complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus
Current Diabetes Reviews Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design Relation Between URIC Acid Levels and Subclinical Hypothyroidism in Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design MicroRNAs: Biomarkers for Cardiovascular Disease in Patients with Diabetes Mellitus
Current Topics in Medicinal Chemistry Flavonoids and Linderone from Lindera oxyphylla and their Bioactivities
Combinatorial Chemistry & High Throughput Screening Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Current Medicinal Chemistry Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets